메뉴 건너뛰기




Volumn 2, Issue 1, 2004, Pages 69-72

Counterpoint: The case Against adjuvant high-dose interferon-α for melanoma patients

Author keywords

Adjuvant immunotherapy; Interferon ; Melanoma; Randomized trials; Survival rates

Indexed keywords

ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT;

EID: 70350075572     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2004.0005     Document Type: Article
Times cited : (5)

References (15)
  • 1
    • 0035880957 scopus 로고    scopus 로고
    • Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system
    • Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19:3622-3634.
    • (2001) J Clin Oncol , vol.19 , pp. 3622-3634
    • Balch, C.M.1    Soong, S.J.2    Gershenwald, J.E.3
  • 2
    • 0030030347 scopus 로고    scopus 로고
    • Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684
    • Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7-17.
    • (1996) J Clin Oncol , vol.14 , pp. 7-17
    • Kirkwood, J.M.1    Strawderman, M.H.2    Ernstoff, M.S.3
  • 3
    • 1842520646 scopus 로고    scopus 로고
    • Interferons and adjuvant therapy
    • Balch C, Houghton AN, Sober A, Soong S-J, eds., St. Louis, MO: Quality Medical Publishing, Inc.
    • Agarwala S, Kirkwood JM. Interferons and adjuvant therapy. In: Balch C, Houghton AN, Sober A, Soong S-J, eds. Cutaneous Melanoma. St. Louis, MO: Quality Medical Publishing, Inc., 2003:605-621.
    • (2003) Cutaneous Melanoma , pp. 605-621
    • Agarwala, S.1    Kirkwood, J.M.2
  • 6
    • 0036534376 scopus 로고    scopus 로고
    • Interferon alfa therapy for malignant melanoma: A systematic review of randomized controlled trials
    • Lens MB, Dawes M. Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials. J Clin Oncol 2002;20:1818-1825.
    • (2002) J Clin Oncol , vol.20 , pp. 1818-1825
    • Lens, M.B.1    Dawes, M.2
  • 7
    • 0034088027 scopus 로고    scopus 로고
    • High-and lowdose interferon alfa-2b in high-risk melanoma: First analysis of intergroup trial E1690/S9111/C9190
    • Kirkwood JM, Ibrahim JG, Sondak VK, et al. High-and lowdose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000;18:2444-2458.
    • (2000) J Clin Oncol , vol.18 , pp. 2444-2458
    • Kirkwood, J.M.1    Ibrahim, J.G.2    Sondak, V.K.3
  • 8
    • 0001574743 scopus 로고    scopus 로고
    • Interferon-α as adjuvant therapy for melanoma: A Meta-analysis of the randomised trials
    • San Francisco, CA, May 15
    • Wheatley K, Hancock B, Gore M, et al. Interferon-α as adjuvant therapy for melanoma: a Meta-analysis of the randomised trials. Proceedings of ASCO, San Francisco, CA, May 15, 2001, Vol. 20.
    • (2001) Proceedings of ASCO , vol.20
    • Wheatley, K.1    Hancock, B.2    Gore, M.3
  • 10
    • 7144264391 scopus 로고    scopus 로고
    • Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group
    • Pehamberger H, Soyer HP, Steiner A, et al. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol 1998; 16:1425-1429.
    • (1998) J Clin Oncol , vol.16 , pp. 1425-1429
    • Pehamberger, H.1    Soyer, H.P.2    Steiner, A.3
  • 11
    • 7144228601 scopus 로고    scopus 로고
    • Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma
    • Grob JJ, Dreno B, de la Salmoniere P, et al. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet 1998;351:1905-1910.
    • (1998) Lancet , vol.351 , pp. 1905-1910
    • Grob, J.J.1    Dreno, B.2    De La Salmoniere, P.3
  • 12
    • 0035883950 scopus 로고    scopus 로고
    • Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: A randomised trial
    • Cascinelli N, Belli F, MacKie RM, et al. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet 2001; 358:866-869.
    • (2001) Lancet , vol.358 , pp. 866-869
    • Cascinelli, N.1    Belli, F.2    MacKie, R.M.3
  • 13
    • 0035805053 scopus 로고    scopus 로고
    • Adjuvant interferon alpha 2b in high risk melanoma - The Scottish study
    • Cameron DA, Cornbleet MC, Mackie RM, et al. Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study. Br J Cancer 2001;84:1146-1149.
    • (2001) Br J Cancer , vol.84 , pp. 1146-1149
    • Cameron, D.A.1    Cornbleet, M.C.2    MacKie, R.M.3
  • 14
    • 0035339880 scopus 로고    scopus 로고
    • High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIb-III melanoma: Results of intergroup trial E1694/S9512/C509801
    • Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIb-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001;19:2370-2380.
    • (2001) J Clin Oncol , vol.19 , pp. 2370-2380
    • Kirkwood, J.M.1    Ibrahim, J.G.2    Sosman, J.A.3
  • 15
    • 0035967235 scopus 로고    scopus 로고
    • Paroxetine for the prevention of depression induced by high-dose interferon alfa
    • Musselman DL, Lawson DH, Gumnick JF, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001;344:961-966.
    • (2001) N Engl J Med , vol.344 , pp. 961-966
    • Musselman, D.L.1    Lawson, D.H.2    Gumnick, J.F.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.